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Breast cancer genome and transcriptome
integration implicates speciﬁc mutational
signatures with immune cell inﬁltration
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A recent comprehensive whole genome analysis of a large breast cancer cohort was used to link known and
novel drivers and substitution signatures to the transcriptome of 266 cases. Here, we validate that subtype-
speciﬁc aberrations show concordant expression changes for, for example, TP53, PIK3CA, PTEN, CCND1 and
CDH1. We ﬁnd that CCND3 expression levels do not correlate with ampliﬁcation, while increased GATA3
expression in mutant GATA3 cancers suggests GATA3 is an oncogene. In luminal cases the total number of
substitutions, irrespective of type, associates with cell cycle gene expression and adverse outcome,
whereas the number of mutations of signatures 3 and 13 associates with immune-response speciﬁc gene
expression, increased numbers of tumour-inﬁltrating lymphocytes and better outcome. Thus, while earlier
reports imply that the sheer number of somatic aberrations could trigger an immune-response, our data
suggests that substitutions of a particular type are more effective in doing so than others.
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T
he recent advance in DNA sequencing technologies has
added substantially to the knowledge-base of breast cancer,
but also reafﬁrmed its proverbial heterogeneity1–8.
Sequencing DNA to greater depth enables analyses in
distinguishing the ‘driver’ mutations—thought to be involved in
the tumourigenesis—from the ‘passenger’ mutations—those
arising in the lifetime of the cancer cell, without affecting the
cancer cell’s ﬁtness. We recently reported on the identiﬁcation of
12 substitution and 6 rearrangement signatures, as well as 7
consensus patterns therein, using whole genome sequence (WGS)
data of 560 cases with primary breast cancer9. Numbered
according to an earlier scheme2, some of the 12 substitution
signatures had underlying mechanisms likely explaining the
signature: for example, signature 1 was described as ‘age-related’
due to the many C4T mutations in an NCG trinucleotide
context (the underlined base is mutated). Similarly, signatures 2
and 13 were related to APOBEC-type mutations (predominant
C4T and C4G in a TCN context, respectively), while signature
3 lacked speciﬁc features but was strongly associated with
inactivated BRCA1 and BRCA2. Signature 5 (with unknown
causal mechanism) is present in most cases and is primarily
characterized by C4T and T4C mutations. Other signatures
were found in few cases (for example, signatures 6, 20 and 26)
showing signs of mismatch repair deﬁciency9. It is important to
realize that most of the breast cancer cases exhibit a blend of these
signatures, possibly obfuscating the resulting effects. The very
diverse pattern of mutations found in primary breast cancer was
previously studied in depth1 in a large cohort, integrating
(epi)genomic, transcriptomic and proteomic data, but this study
mainly focused on the driver genes and reported the resulting
effect on its expression in solo or in concert in pathway analyses.
The possible effects of the mutational signatures themselves on
the transcriptome have been studied with less scrutiny.
In the current study we analyse the transcriptome of 266 cases
(191 ER-positive/Her-2 negative and 75 triple-negative) by RNA
sequencing with available WGS results9 to explore the possible
consequences of the substitution signatures at the transcriptome
level. We report on clinically and biologically relevant gene
expression signatures and associate these with the number and
character of signature mutations.
Results
Validation of cohort. RNA-sequencing data of 266 primary
breast cancer cases with available WGS data were generated and
were ﬁrst analysed and visualized to verify whether the cohort
exhibited the archetypical breast cancer patterns. To this end, the
5,000 most variable transcripts were used to correlate and hier-
archically cluster all cases resulting in ﬁve clusters (Fig. 1). Cluster
1 contained all cases of the basal-like intrinsic subtype6,10 and
held 92% of ER-negative cases, while the remaining four
subclusters (clusters 2–5) were luminal. Among the subtypes,
the total number of substitutions was highest in the basal-likes
(Kruskal–Wallis (KW) Po0.0001), while within the luminal
cases, the more aggressive luminal B (refs 11,12) compared with
luminal A type cancer also showed higher numbers of
substitutions (Mann–Whitney U-test (MWU) Po0.0001,
Supplementary Fig. 1, and previously reported1).
Next, we evaluated the reported driver genes (derived from
WGS data9) with at least ﬁve events in this cohort (with the top
recurrent events presented in Fig. 1). Ampliﬁcation of MYC
(n¼ 47, w2 Po0.0001), of CCNE1 and CCND3 (both n¼ 7, w2
P¼ 0.0003), of PIK3CA (n¼ 9, w2 Po0.0001) and, as expected,
mutations in TP53 (refs 12–14) (n¼ 105, w2 Po0.0001) were
predominant in basal subtype cancers, while mutations in
GATA3(refs 8,15) (n¼ 25, w2 P¼ 0.0006), and PIK3CA (n¼ 74,
w2 Po0.0001) and ampliﬁcation of CCND1 (n¼ 39, w2
Po0.0001) were largely restricted to luminal breast cancer,
with the latter strongly related to luminal B cancers16,17 (33/39
cases, w2 Po0.0001). The lobular cancer driver18,19 CDH1 was
mutated in lobular cases (15/21, w2 Po0.0001) and mutations of
this type were predominantly observed in luminal A cases (12/21,
w2 P¼ 0.0013). In line with their oncogenic role, ampliﬁed
regions had signiﬁcantly higher expression for MYC, CCND1,
ZNF217, PIK3CA, MDM2, CCNE1, IGF1R, KRAS and ERBB2
(MWU all Po0.05, Supplementary Fig. 2). The 8p11 locus was
identiﬁed as recurrently ampliﬁed as well, wherein, for example,
FGFR1, ZNF703 and WHSC1L1 are potential driver candidates.
These three genes are indeed signiﬁcantly higher expressed in the
ampliﬁed cases (data not shown) precluding isolation of the
actual driver from the passenger genes. Tumour suppressors
showed lower expression in cases with mutations (CDH1 and
PTEN; MWU Po0.0001, Supplementary Fig. 2). For TP53,
however, the type of mutation mattered (Supplementary Fig. 3)
with obvious deleterious variants such as frameshifts (n¼ 19,
MWU P¼ 0.002) and nonsense substitutions (n¼ 19, MWU
Po0.0001) clearly showing lower expression, while increased
expression of TP53 was found in samples with missense
substitutions (n¼ 47, MWU Po0.0001) supportive of a
potential tumour promoting role of some of these latter type of
TP53 variants20. The type of mutation was furthermore associated
with copy neutral LOH (Fisher’s Exact P¼ 0.021), with cases with
missense mutations showing less than expected numbers with
copy neutral LOH (17.8 expected, 9 observed), again supportive
for a dominant role of missense mutations in the TP53 gene
(Supplementary Fig. 3). Finally, we validated earlier reported1
mutual exclusivity of PIK3CA aberrations, a predominant driver
in breast cancer, with any event in PTEN, AKT1 or AKT2 in all
560 cases. Of the 167 cases with a PIK3CA aberration, the
majority (91%) lacked any event in the three abovementioned
genes (P¼ 3.6e-5 coMEt exact test21, Supplementary Fig. 4)
suggesting these are core constituents in this driver pathway in
breast cancer.
As indicated, many of these observations were reported earlier,
conﬁrming the validity of our cohort for subsequent analyses.
However, a few additional observations were noted for known
driver genes; for CCND3, solely found ampliﬁed in basal cases,
similar expression levels were observed in all but one sample of
the ampliﬁed cases compared with diploid cases, implying
CCND3 is likely not the sole driver in this ampliﬁed region
(Fig. 2, top left). TCGA results (n¼ 960 cases) conﬁrmed our
ﬁnding but did show a signiﬁcant increase in expression levels of
CCND3 (ANOVA Po0.0001) in ampliﬁed cases supportive of it
being an oncogene (Fig. 2, top right). However, with the mean
log2 expression level in ampliﬁed cases being only 1.2-fold higher
compared with diploid cases, this is not the effect one would
expect from a biological relevant driver in a particular ampliﬁed
genomic region. Evaluating genes in the vicinity (B700 kb) of
CCND3, only USP49 and BYSL could be considered as putative
drivers instead, showing a more than 3 fold higher expression in
the ampliﬁed cases in our cohort. In TCGA data, differences were
less pronounced, with BYSL showing the largest fold-change
(1.5 ) (Supplementary Fig. 5a).
Next to the above, in our cohort increased GATA3 expression
was observed in the 25 cases with GATA3 mutations (MWU
Po0.0001, Fig. 2 bottom panel), which may point to a dominant,
activating role for mutations in this gene. TCGA results
conﬁrmed (ANOVA Po0.0001) this, showing a threefold higher
expression found in GATA3 mutated (n¼ 95) compared with
wild-type cases (n¼ 864). The vast majority of mutations were
found in exon 5 and 6 (22/25 in our cohort and 90/95 in TCGA),
but no signiﬁcant difference was seen in expression levels between
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exon 5 or 6 mutated cases, thus expression changes are
independent of the fact that exon 5 mutations predominantly
are frameshifts leading to shorter proteins and exon 6 mutations
are frameshifts causing proteins with a C-terminal extension
(Supplementary Fig. 5b). Noteworthy, the 4% of TCGA cases with
an ampliﬁcation of GATA3 showed signiﬁcantly lower expression
levels compared with diploid cases (sixfold reduction, ANOVA
Po0.0001, data not shown).
Cell cycle and immune pathways and mutational signatures.
Switching from single genes to studying the effects of the various
substitution signatures9 on the global transcriptome, we ﬁrst
studied the molecular subtypes in relation to the signatures.
Signiﬁcantly higher numbers of signature 3 substitutions but
lower number of signature 2 substitutions were found in the basal
subtype (KW both Po0.0001) compared with the other subtypes.
Substitutions of signature 5 were more abundant in the Her-2
group (KW Po0.0001) while signatures 8 and 13 again showed
increased numbers in the basal subtype (KW both Po0.0001).
Additional details can be found in Supplementary Fig. 6.
To further evaluate transcriptomic pathways and substitution
signatures, we grouped samples according to their dominant
mutation signature and compared the cases with, to those lacking
that dominant signature (Methods section). The most prominent
pathways emerged in ER-positive cases (Supplementary Table 1/
Supplementary Fig. 7) and related to cell cycle, which was
signiﬁcantly associated with the total number of substitutions,
while several immune-response pathways were found associated
with cases showing predominantly signatures 2 and/or 13. These
latter substitution signatures have been accredited5 to activity of
the APOBEC/AID family of cytidine deaminases, targeting the
TCN trinucleotide sequence (the underlined base gets mutated).
In ER-negatives, several metabolism related pathways were found
related with signature 3 substitutions, but these were
predominantly driven by few genes or otherwise were always
higher expressed in cases with low numbers of that signature
(green bars in the geneplot, Supplementary Fig. 7a), giving less
conﬁdence that these pathways were of interest. In contrast, the
cell cycle pathways consistently showed multiple genes higher
expressed in the ER-positive cases with high numbers of
the signature (see Supplementary Fig. 7b,c for examples).
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Figure 1 | Clustered correlation matrix of 266 breast cancer cases. The left panel shows the dendrogram and clustered correlation matrix (red is positive,
blue negative correlation) of 266 breast cancer cases. The top 5,000 most variable transcripts were used for correlating the samples. For the columns in
the right panel, colour codes are as follows: ER: ER-positive dark grey, ER-negative light grey. Subtype: Red, basal; dark blue, Luminal B; light blue, Luminal A;
green, normal-like; and dark yellow, her2. Grade: white, NA; light grey, grade 1; grey, grade 2; and black, grade 3. Tissuetype: red, ductal; blue, lobular; light
blue, micropapillary; grey, mucinous; dark yellow, papillary; yellow, apocrine; and dark green, other type. # subs: The length of the green bar is proportional
to the number of substitutions. Cases with 410,000 substitutions are shown with a soft-red coloured bar of equal length. The remaining nine columns
show the status of driver genes. Light grey, wild type; dark yellow, copy-number ampliﬁcation; blue, homozygous deletion; and mutations (substitution,
indels, rearrangements) are dark green if activating and red if inactivating.
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To validate the pathway results, we studied cell cycle and
immune-related gene expression signatures in further detail.
As an objective readout of the cell cycle phenotype,
we used genes annotated to the mitotic cell cycle (MCC,
GeneOntology:0000278) and associated global expression of these
genes to the number and type of substitutions (signatures 6, 17,
20, 26 and 30 were excluded since very few cases harboured these
substitution types) and also to pathological grade (Fig. 3a). Next
to conﬁrming that the total number of substitutions were higher
in the top quartile of samples with high MCC gene expression
(MWU Po0.0001), we found that several signatures did
similarly, especially signatures 13, 8, 1 and 3 (MWU Po0.0001,
P¼ 0.0002, P¼ 0.002 and P¼ 0.005, respectively). Insofar data
were available, pathological grade III was also clearly enriched in
the top quartile (w2 Po0.0001). Thus, irrespective of the type of
signatures identiﬁed in a patient, a higher number of substitutions
was related to increased cell proliferation. Adverse outcome is
thus to be expected in patients with a high mutational load, and
this was conﬁrmed by evaluating overall and relapse-free survival
data (Fig. 3b,c).
The other major theme in the analysis of the transcriptome was
the involvement of immune response in relation with particularly
the APOBEC-type substitution signatures 2 and 13, also in
ER-positive cases. Revisiting the pathway results (Supplementary
Fig. 7c) showed a clear association of, for example, IFNG, CTLA4
and several chemokines with these 2 APOBEC-signatures,
substantiating a relation with T-cell response. To study
objectively if indeed activation of the immune system is
mutational signature speciﬁc, we related in ER-positive cases
(n¼ 192) a previously developed tumour-inﬁltrating lymphocytes
(TIL) RNA expression signature for breast cancer22 to the diverse
mutational signatures, again excluding signatures 6, 17, 20, 26
and 30 due to low numbers (Fig. 4 and Table 1). Samples with
overall high expression of the TIL-signature genes (top quartile
of cases) had a signiﬁcantly higher number of signature 13
(MWU P¼ 0.0027) and also of signature 3 (MWU P¼ 0.027). In
contrast, the age-related signature 1 (MWU P¼ 0.0005) displayed
a signiﬁcantly lower number in the high TIL group. The number
of mutations of the other signature types was not signiﬁcantly
associated with high TIL expression. Next to analysing absolute
numbers, we also analysed the data proportionally, by correcting
for the total number of mutations, which removes total
mutational load as possible confounding factor but this analysis
yielded comparable results (Supplementary Table 2).
Even though the number of patients at risk is low, patients with
high TIL and low MCC have a signiﬁcantly better outcome than
those with low TIL and high MCC (Fig. 5a,b). We validated
this ﬁnding in an independent cohort of 625 lymph-node
negative, not (neo)adjuvantly hormonal/chemotherapy treated
cases (Fig. 5c). The TIL and MCC groups analysed separately
also show signiﬁcant survival differences in this independent
cohort (logrank P¼ 0.001 and Po0.0001 for TIL and MCC,
respectively. See Supplementary Fig. 8) and when TIL and MCC
groups were analysed in a multivariate model, both remained
signiﬁcant (TIL Hazard Ratio 0.53 (95% conﬁdence interval (CI)
0.36–0.79), P¼ 0.002 and MCC HR 1.81 (95% CI 1.33–2.47),
Po0.0001).
Next, we investigated the pathological inﬁltrate status in all
ER-positive cases (n¼ 266, which includes those without RNAseq
data). We associated the number of mutations per signature with
the pathological inﬁltrate status. Lymphocytic inﬁltrate was
grouped into three groups, having no, mild and moderate-severe
inﬁltrate, and a test for trend across ordered groups showed
signiﬁcantly higher numbers of signatures 3 and 13 (both
Po0.0001, see Table 2) in cases with increasing inﬁltrate, with
signature 2 (the other APOBEC signature) showing a weak
association as well (test for trend P¼ 0.022). Of note, the results
for signature 3 may be hampered by the fact that many cases lack
signature 3 mutations entirely; of the n¼ 266 cases in this
analysis 230 (86%) have zero signature 3 mutations. An analysis
with the proportion of substitutions of a signature yielded largely
similar results (Supplementary Table 3), in the sense that
signatures 3 and 13 remain strongly associated with the inﬁltrate
status (test for trend Po0.0001), whereas signature 1 and 5
showed higher proportions in cases with decreasing inﬁltrate
(test for trend P¼ 0.015 and Po0.0001, respectively). To exclude
that individual drivers themselves were not responsible for the
observed association we investigated if mutation (including
substitution, indel, rearrangement, copy-number variation) of
the driver genes was directly associated with inﬁltrate levels. The
following genes were analysed: ARID1A, CCND1, CDH1, GATA3,
MAP2K4, MAP3K1, MLL3, MYC, PIK3CA, PTEN, TP53 and
ZNF217 (n¼ 10, 32, 17, 22, 17, 20, 11, 21, 64, 13, 33 and 11,
respectively), but none of the investigated genes was found to be
signiﬁcantly associated with inﬁltrate status (Fisher’s Exact test,
P40.05).
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Amino acid properties and immune response. To try to
understand why only certain mutation signatures relate to a
more effective immune response, we determined in-silico which
substitutions yield predicted neo-epitopes23,24 but found no
striking signature speciﬁc difference in the fraction of predicted
neo-epitope presenting substitutions (Supplementary Fig. 9a). We
also studied the altered chemical properties25,26 of the mutational
signature induced amino acid changes. However, changes in
hydrophobicity (Supplementary Fig. 9b) were not strongly
differently proportioned across the substitution signatures. In
contrast, amino acid substitutions resulting from particularly
signature 13 but also from signature 2 displayed a clear increase
in charge (Supplementary Fig. 9c), while substitutions caused by
signature 1—which were associated with lower inﬁltrate—
displayed a loss of a charge instead. The number of signature
13 substitutions that lead to an increase in charge was
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16 8
High:80
Low:105
6 0
0 60 120
At risk:
23 13
High:108
Low:133
14 1
0 60 120
At risk:
High
Low
# Subs, overall survival
1.00
0.80
0.60
0.40
0.20
0.00
1.00
0.80
0.60
0.40
0.20
0.00
M
ito
tic
 c
el
l c
yc
le
 g
en
es
a
b c
P=0.03
# Subs, relapse free survival
Low
High
Sig. 13
Sig. 8
Sig. 3
Sig. 1
# Subs
Grade
Average
MCC
Figure 3 | Mitotic cell cycle gene activity related to mutational signatures and outcome. (a) The average expression of genes (n¼409) from
Gene-Ontology term Mitotic Cell Cycle (GO:0000278) were used to rank ER-positive samples. The vertical black line indicates the third quartile border.
Top panel: heatmap of median centred expression values in log2-FPKM, red indicates above median, blue below median expression. Genes are in rows,
samples in columns. Below the heatmap: ‘Average MCC’ shows the average expression of the cell cycle genes. Grade: pathological grade; white, NA; light
grey, grade 1; grey, grade 2; and black, grade 3. Last ﬁve rows: the length of the green bar is proportional to the number of substitutions. # subs: the total
number of substitutions, samples with 410,000 substitutions are shown with a soft-red coloured bar and are of equal length. For the columns labelled
Sig. 1, 3, 8 and 13, soft-red indicate samples 43,000 of such substitutions. (b,c) Overall and relapse-free survival Kaplan–Meier curves. Blue indicates
patients with less than the median number of substitutions, red indicates higher than median. P values are logrank-test values. The x-axis shows
time in months, y-axis shows the proportion of surviving patients.
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signiﬁcantly associated with increasing lymphocytic inﬁltrate (test
for trend Po0.0001); a similar test for signature 2 substitutions
showed a P value of 0.014. Analysing the total number of
substitutions leading to increased electric charge, irrespective of
signature type, also showed increasing numbers with increasing
lymphocytic inﬁltrate (test for trend Po0.0001) which remained
signiﬁcant even when signature 13 substitutions were excluded
(test for trend Po0.0001).
Discussion
In this paper we investigated the mutation signatures present in
primary breast cancer and their relation to the transcriptome.
Although somewhat impeded by the fact that most tumours
display a multiplicity of signatures, we were able to show that
individual signatures have speciﬁc effects on the gene expression
phenotype of tumour cells. As may be noted from the results,
the main observations were obtained in ER-positive cases. The
lack of results in ER-negative cases is attributed to the more
homogeneous nature of this subtype; for example, virtually all
ER-negative patients have high inﬁltrate levels (in our cohort only
four cases display a nill inﬁltrate phenotype) and a high
mutational load (just two ER-negative cases are among the
bottom 20% after ranking on mutational load), which impedes
identifying expression differences due to the lack of a sizeable
contrast group.
Regarding the global transcriptome in relation to the
substitution signatures, ﬁrst, we observed that the total number
of substitutions was positively associated with expression of cell
cycle genes, independent of which of the individual substitution
signatures contributed to the total. Reviewing the driver genes,
as expected CCND1 and MYC ampliﬁed cases, as well as TP53
mutated cases were enriched in the top quartile MCC expression
(Fisher’s Exact test, all Po0.0001). The relation between an active
cell cycle and various known drivers of cell cycle progression
(CCND1, MYC, TP53) and poor outcome in ER-positive patients
has been widely investigated16,27–31, thus our observation that the
mutational burden (deﬁned here as the total number of
substitutions, regardless of type) was also associated with
shorter DFS and OS may be not surprising. The association of
mutational burden and poor outcome in ER-positive patients was
described earlier as well32, but using data based on exome
sequencing, which we ﬁrmly validated here using whole genome
sequencing data, with the latter enabling removal of the possible
bias which may exist on the total mutational burden derived from
the transcribed part (exome) compared with the entire genome
(WGS). Noteworthy is that both mutational signatures which are
replication dependent (for example, signature 13) and those that
are not (for example, signature 8)9 contribute to the mutational
burden. This suggests that mutational load as a result of
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log2-FPKM, red indicates above median, blue below median expression. Genes are in rows, samples in columns. Below the heatmap: the ﬁrst row shows the
average expression of the TIL genes. Last three rows: the length of the green bar is proportional to the number of substitutions of the indicated signatures.
Samples with 43,000 substitutions are shown with a soft-red coloured bar and are of equal length.
Table 1 | Association of the number of substitutions per
signature by TIL-signature group.
Signature n MWU* Average high TIL Average low TIL
1 183 0.0005 532.8 752.5
2 179 0.64 2,313.1 328
3 24 0.027 581.4 209.5
5 166 0.27 1,033 1,022.2
6 2 N.D. 17,791 0
8 123 0.59 663.6 453.3
13 115 0.0027 1,897 309.5
17 6 N.D. 9.7 23
18 32 0.39 37.8 64.4
20 1 N.D. 0 0
26 3 N.D. 171.5 87.6
30 1 N.D. 0 0
N denotes the number of samples with 40 of a particular substitution signature. The average
number of substitutions is listed per TIL-signature group; high TIL indicates the top quartile of
samples, low TIL the rest of the samples.
*P value of MWU.
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insufﬁcient or improper repair during DNA replication, as well as
those from other sources, both contribute to more rapid
progression of ER-positive disease.
Second and interestingly, we observed a signiﬁcant, positive
relation between substitutions of signatures 13 and 3 and a TIL
gene expression signature and also to increasing levels of TILs.
The association of signature 3 substitutions with immune-
response pathways is not readily explained by the type
of substitutions—which are broadly patterned—or by the
investigated amino acid properties; we speculate that the strong
association of signature 3 with inactivated BRCA1/2 (ref. 9) could
make this signature a proxy for BRCA-ness (with its particular
rearrangements) in ER-positive cases. Inactivated BRCA is tightly
linked with loss of homologous recombination (HR) repair
mechanisms, leading to distinct rearrangement patterns9. We
speculate that these rearrangements, which can comprise up to
hundreds of events in a sample, leading to randomly aberrant
proteins, potentially triggering an immune response. And,
although the exact modus operandi of how signature 3 or
BRCA-ness could increase immune response is as of yet obscure,
higher lymphocytic inﬁltrate have been previously reported in
familial BRCA1 (ref. 33) and BRCA2-affected tumours34, the
former study also showing signiﬁcantly better relapse-free
survival for BRCA-patients with higher inﬁltrate levels.
The connection between TIL and signature 13 substitutions
may be based on the distinguishing feature of signature 13;
its clear APOBEC pattern2,5, deaminating cytidines in a TCN
context, favouring C to G substitutions. We hypothesize that TILs
are enriched at sites where the proper peptides are presented; a
possible way signature 13 substitutions could activate this
immune-response is via its resulting neo-epitopes. One
difference we observed for altered peptide sequences resulting
from signature 13 substitutions as compared with other equally
abundant ones originating from other sources (for example,
signature 1, 5, 8 substitutions) was not the number of predicted
neo-epitopes, but rather its tendency to being positively charged.
The observed increase in charge in signatures 2 and 13 can be
readily explained by the fact that these signatures frequently affect
the only two negatively charged amino acids Glu and Asp,
respectively, which are modiﬁed in this mutational context into
Lys (signature 2) and His (signature 13), both positively charged.
Thus, these latter 2 signatures are most efﬁcient in generating
mutated peptides with increased electric charge. Interestingly,
patients with an increased lymphocytic inﬁltrate showed,
irrespective of signature type, higher numbers of positively
charged amino acid substitutions, indicating that the association
of signature 13 with TIL might be because positively charged
amino acids are more commonly generated in this signature type.
Concluding, we show that ER-positive breast cancer
responds to DNA mutations with two speciﬁc changes in the
transcriptome. On the one hand, the cell cycle with its associated
adverse clinical outcome appears to be more active with an
increasing number of mutations, regardless of their underlying
signatures. On the other hand, we observe a signature speciﬁc
association with immune response, possibly arising from an
increased number of neo-antigens that consequently may
stimulate the immune response more effectively. However,
independent conﬁrmation of our ﬁnding is needed as well as
mechanistic studies explaining the observed association. Still, our
results augment earlier reports35–37, which postulate that a high
mutational load is sufﬁcient for the immune system to sense one
or more neo-epitopes as non-self. However, by untangling the
mutational load into speciﬁc signatures, our results suggest that
the breast tumour cell, while gaining advantage by those
mutations stimulating proliferation, may inadvertently provoke
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Figure 5 | Combined MCC and TIL-signature genes and outcome. Overall (a) and relapse-free (b) survival KaplanMeier curves of our cohort and
(c) metastasis-free survival of independent in-house and public data sets. Green line indicates patients with high expression of TIL genes (top quartile) and
low expression of MCC genes (bottom three quartiles). The red line indicates patients with low expression of TIL genes and high expression of MCC genes.
Blue indicates the remaining patients. P values are logrank-test for trend values. The x-axis shows time in months, y-axis shows the proportion of patients.
For the numbers at risk, 1 indicates the highTIL/lowCC group (green line), 3 indicates the lowTIL/highCC (red line) and 2 the remaining patients.
Table 2 | Association of the number of substitutions per
signature by lymphocytic inﬁltrate group.
Signature N Cuzick* Average
nill
Average
mild
Average
moderate/severe
1 253 0.537 592.9 728.5 649.9
2 248 0.022 169.5 657.7 1,401.5
3 36 o0.0001 127.7 197.8 944.2
5 237 0.158 1,131.2 1,040.7 1,059.4
6 2 N.D. 0 54.9 355.8
8 172 0.117 322.4 435 785.4
13 174 o0.0001 91.5 573.1 1,613.9
17 9 N.D. 11.7 20.9 14.5
18 45 0.935 32.6 90.3 34.2
20 0 N.D. 0 0 0
26 3 N.D. 0 126 164.6
30 0 N.D. 0 0 0
N denotes the number of samples with 40 of a particular substitution signature. The average
number of substitutions is listed per lymphocytic inﬁltrate group.
*P value of Cuzick’s nonparametric test for trend across ordered groups.
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the immune system more effectively if the mutational load is
moulded through speciﬁc mutational processes. Exploiting this
knowledge by purposefully augmenting T-cell reactivity against
amino acid substitutions resulting from the proper DNA
substitution type could improve cancer immunotherapies.
Methods
Cohorts. The sample cohort used in the study has been described in detail
recently9. To recapitulate, DNA and RNA of breast cancer tumours were analysed
using WGS (WG-DNA data), copy-number analysis, methylation proﬁling, RNA
sequencing and miRNA analysis. Here, we studied all patients with available
RNAseq and WG-DNA data (n¼ 266, no replicates). Sequencing protocols, QC
and post-processing of data as well as the DNA substitution and rearrangement
signatures and data availability are described elsewhere9. For the RNA-sequence
cohort, IHC-scored Her2-positivity (as ascertained by a panel of pathologists
according to the current standard practice) was an exclusion criterion, though at
the time of analysis, some cases showed DNA ampliﬁcation of the Her2 locus. Gene
expression values were available as log2-FPKM values for 49,738 transcripts. For
the correlation matrix (Fig. 1) transcripts with420% missing data were excluded,
and the top 5,000 variable transcripts—which included besides 3,484 protein-
coding genes, 1,516 non-coding RNA species such as lincRNAs, snRNAs and
snoRNAs and so on—were median centred and used to correlate (Pearson) all
samples with each other. The resulting correlation matrix was hierarchically
clustered38 (Cluster 3.0) using uncentered correlation as distance metric. The
molecular subtypes were established using the AIMS method6.
Pathway analysis. Since the transcriptome is heavily driven by ER-status, pathway
analyses were performed within ER-positive and -negative breast cancer cases
separately. In the pathway analysis each signature was analysed separately: the
proportion of substitutions of a particular signature was used for grouping samples.
Samples which had at least 50% of a particular signature were compared with
samples having o20% of such substitutions, where both groups should have at
least 15 cases. In ER-positive cases, signature 5 (n¼ 54 450% proportion versus
n¼ 32 o20%) and the APOBEC-signatures (Sig 2þ 13 combined) with n¼ 18
450% proportion versus n¼ 45 o20%) were available for analysis and in
ER-negative cases, signature 3 (n¼ 24 450% versus n¼ 22 o20%) could be
evaluated. In addition, disregarding the type of signature, the total number of
substitutions was used to group samples with the most extreme number of
substitutions (top and bottom 20%). Initially samples were grouped in a low and
high mutational burden group, separately for ER-positive and -negative cases.
However, in the ER-negatives, samples in the bottom 20% still had a high absolute
number of substitutions. Since our aim was to identify differential pathways
associated with the absolute tumour burden, we wanted to have a bottom 20%
group with absolute low numbers of substitutions. Samples were thus ranked
according to mutational burden independent of ER-status to obtain the bottom and
top 20% groups. In ER-positive cases, this gave a group of n¼ 15 in the top 20%
versus n¼ 52 in the bottom 20%. In ER-negative cases there were only two samples
in the bottom 20%, precluding a meaningful analysis. Pathway analysis were
performed using the R-package ‘global test’39 using Biocarta (www.biocarta.com)
and KEGG (ref. 40) as annotation databases. All P values were corrected for
multiple testing (Bonferroni–Holm) and checked by re-sampling 1,000 times to
ascertain the number of times an equally sized, randomly chosen group of genes is
at least as signiﬁcant as the true set of genes belonging to a pathway. Pathways were
considered of interest if the P value of the global test after correcting for multiple
testing and the re-sampling P value were both below 0.05. Second, pathways were
considered relevant pathways if these consistently showed multiple genes higher
expressed in the cases with high numbers of a signature.
Neo-antigen prediction and hydrophobicity of amino acids. To ascertain which
of the amino acid changing substitutions potentially contain a neo-epitope,
all unique, non-silent, non-terminating amino acid substitutions were selected
(n¼ 26,475) and we focused our analyses on CD8 T-cell epitopes. FASTA ﬁles of
the wild-type sequences were obtained via the consensus coding sequence database
(http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi) and custom Perl scripts
were used to mutate the wild-type sequence according to the identiﬁed substitution
in our cohort. Since the software to evaluate neo-epitopes uses all possible 9-mer
peptides in a sequence, we selected a 17-mer sequence with the mutated amino acid
in the middle – thus making sure the mutated amino acid was always present in all
possible 9mers of that sequence. Care was taken if the substitution was too near to
the start or end of a gene to ensure a 9mer was always present. The mutated
FASTA sequences were uploaded to NETMHC v3.4 (refs 23–24) (http://
www.cbs.dtu.dk/services/NetMHC/ ) to predict the binding afﬁnity to the following
HLA-A2 alleles, representing the most prevalent MHC class I alleles among the
Caucasian population: HLA-A2:01, 02, 03, 06, 11, 12, 16, 17, 19 and 50. With a
possible eight sequences to be tested per gene, this gives a matrix of at most 80
predictions. As deﬁned23, a predicted EC50o50 nM of a peptide towards HLA-A2
alleles indicates a ‘strong binder’ and if any of the possible predictions was found
o50 nM the gene was considered harbouring a potential neo-antigen.
Changes in hydrophobicity of mutated amino acids was ascertained using the
scale of Kyte & Doolittle41 where the level of the mutated amino acid was
subtracted from the wild-type amino acid. A positive difference (40) was labelled
as ‘increase’ and o0 as ‘decrease’ in hydrophobicity. Changes in electric charge
were evaluated by assigning Aspartic acid and Glutamic acid as negatively charged
and Lysine, Arginine and Histidine as positive. Next, base substitutions were
evaluated if a resulting amino acid change led to a change in electrical charge. Since
all substitutions are assigned to a mutational signature, the total number of charge
changing (and hydrophobicity changing) substitutions per signature was
established.
Independent validation set. In-house and publicly available gene expression data
of lymph-node negative primary breast cancer patients, who were not treated
(neo)adjuvantly with hormonal/chemotherapy and available metastasis-free
survival data were used, leading to a cohort of 867 patients (n¼ 625 ER-positive).
This selection enables a pure study on prognosis. Data were gathered from Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) entries GSE2034,
GSE5327, GSE2990, GSE7390 and GSE11121, with all data available on Affymetrix
U133A chip. Raw.cel ﬁles were processed using fRMA (ref. 42) parameters (median
polish), after which batch effects were corrected using ComBat (ref. 43). The
average expression of TIL genes22 and MCC genes (Gene Ontology:0000278) were
calculated of each sample, and the samples in the top quartile for TIL and the top
quartile for MCC were used to group the patients in three groups; those with high
TIL/low MCC, those with low TIL/high MCC and the remaining patients.
Statistics. Associations between gene expression levels and gene-status (mutant,
ampliﬁcation and so on) were analysed using MWU, or KW when more than two
categories were evaluated. In the analyses where the expression level of a gene was
associated with its own status and not with other genes, no multiple testing
correction was necessary. To test for a trend across ordered groups (for example,
number of substitutions in increasing grade), Cuzick’s nonparametric test for trend
was used, an adjunct to the KW test. Pearson’s w2 test was used to evaluate
categories (for example, mutation status versus molecular subtype) or by Fisher’s
Exact test when number of events were low. Stata v13 (StataCorp, Texas, USA) was
used for the statistical tests and Kaplan–Meier survival curves. A two-sided P value
of o0.05 was considered statistically signiﬁcant.
Data availability. WGS, RNA-seq and methylation data that support the ﬁndings
in this study are available at the European-Genome Phenome Archive (https://
www.ebi.ac.uk/ega) under the accession code EGAS00001001178. For the
validation data, in-house GSE2034 and GSE5327, and otherwise public data
GSE2990, GSE7390 and GSE11121 are available at the Gene Expression Omnibus
website (http://www.ncbi.nlm.nih.gov/geo/). All other data are contained within
the Article and its Supplementary ﬁles or available from the authors on request.
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